Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

March 24, 2017

Patients with drug-resistant tuberculosis (MDR-TB) have to take a fistful of pills and injections daily for up to two years. Side effects of these toxic drugs can include permanent deafness, nausea and vomiting, blindness, and psychosis. After decades without any new TB drugs, two powerful, less toxic medicines were finally released five years ago. But most patients can't get access to them. This needs to change.

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

March 23, 2017

Companies and countries must take urgent action to increase access to these lifesaving treatments

March 21, 2017

Winile is a multidrug-resistant tuberculosis (MDR-TB) patient with Doctors Without Borders/Médecins Sans Frontières (MSF) in Swaziland, and one of the many who have lost their hearing due to the toxicity of available MDR-TB drugs. Through an MSF program in Swaziland, she has learned sign language so she can continue to communicate.

February 23, 2017

"You see, I am healed," says Tholakele as she walks around her ward demonstrating her recovery. "Even my legs don't give me problems anymore. Now I can walk perfectly. I walk around the hospital; go out for fresh air and come back when I’m ready."

Tholakele, 39, has drug-resistant tuberculosis (DR-TB) and started treatment in May 2016 at the Moneni National TB Hospital, supported by Doctors Without Borders/Médecins Sans Frontières (MSF) in central Swaziland.

January 24, 2017

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability

January 19, 2017

NEW YORK, JANUARY 20, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) began a new clinical trial this week in Uzbekistan to develop a radically improved course of treatment for drug-resistant tuberculosis (DR-TB).

The trial aims to find a treatment regimen for DR-TB that is drastically shorter, more effective, and causes fewer side effects than the current treatment options.

November 07, 2016

In an attempt to break up the everyday routine for children undergoing tuberculosis treatment in Tajikistan, the MSF psychosocial team organizes celebration parties as part of MSF’s pediatric therapeutic play program.

October 26, 2016

NEW YORK/LIVERPOOL, OCTOBER 26, 2016 – At the annual Union World Conference on Lung Health, which started in Liverpool today, Doctors Without Borders/Médecins Sans Frontières (MSF) is sharing its experience of using the new tuberculosis drugs bedaquiline and delamanid to treat people with drug-resistant TB. MSF is also involved in two clinical trials to test new TB treatments, both of which will start enrolling patients soon.

October 25, 2016

South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world, with more than 20,000 people diagnosed with DR-TB in 2015. Yet the current DR-TB treatment regimen—which consists of a combination of multiple pills and daily injections—is only successful in about half of all people who receive it. New drugs such as delamanid offer the opportunity to provide more successful, tolerable treatment regimens to patients with few other options available.

Pages